To investigate the effects of intravitreal avastin combined with macular grid photocoagulation for diabetic macular edema(DME)． METHODS: Totally 21 DME cases (29 eyes) were treated with intravitreal 1.5mg avastin followed by macular grid photocoagulation a week later in this nonrandomized, interventional case series. The best-corrected visual acuity (BCVA) was measured and the optical coherence tomography (OCT) findings were examined before and after 1, 3, 6,12 months treatment. The follow-up time varied from 6 months to 12 months (average 7.5 months). RESULTS: The mean BCVA（logMAR）was 0.66±0.19 before treatment and 0.31±0.18 at the last visit (P<0.01). The BCVA improved more than two lines in 21 eyes (72%), improved one or two lines in 6 eyes (21%) and stabilized (no change) in 2 eyes (7%) and none decreased. Macular edema significantly improved in 25 eyes (accounting for 86%), reduced by 30% or more in 20 eyes (accounting for 69%), decreased by 29%-10% in 7 eyes (accounting for 24%), and decreased by 10%-0 in 2 eyes (accounting for 7%).The central macular thickness (CMT) on OCT images decreased from 450.72±74.22μm at baseline to 283.55±44.43μm after treatment(P<0.01). No complication occurred. CONCLUSlON: Combination treatment with intravitreal avastin and macular grid photocoagulation was well tolerated, with an significantly improvement in BCVA, and OCT. This suggests combination treatment with intravitreal avastin and macular grid photocoagulation for diabetic macular edema merits further investigation.